Shamshi Azmi1, Jameel Ahmad1*, Farida Ahmad1, Anjum M Chughtai2
1Department of Pharmacology, JNMC AMU Aligarh (U.P.) India
2Department of Pharmacology and Medicine, JNMC AMU Aligarh (U.P.) India
*Address for Corresponding Author
Department of pharmacology, JNMC AMU Aligarh (U.P.) India
Objective: In the recent past, there were several reports of increased risk of type 2 Diabetes Mellitus with the use of statins. Therefore randomized, prospective, parallel group, open labeled, 24 weeks study of Atorvastatin and Rosuvastatin was done on newly diagnosed cases of dyslipidemia. Methods: This pre-specified analysis was conducted after the last patient completed 24 weeks. Eligible patients were randomized into two groups Group-1 (Atorvastatin) and Group-2 (Rosuvastatin). The two groups were further divided into subgroups based on different doses. At week 24, statistically significant increase in fasting plasma glucose, 2 hour post prandial plasma glucose and haemoglobin A1c was observed with Atorvastatin 10 and 20 mg, and Rosuvastatin 5 and 10 mg. Results: Statins were well tolerated with no evidence of any severe adverse event. Atorvastatin and Rosuvastatin showed an increase in all glycemic parameters (FPG, 2hours PPG, HbA1c); yet none of the subjects entered into overt diabetic range during our study period. Conclusion: Atorvastatin and Rosuvastatin showed an increase in all glycemic parameters (FPG, 2 hours PPG, HbA1c).
Keywords: Atorvastatin, rosuvastatin, glycemic parameters, HbA1C, dyslipidemia